Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)
Phase 2
Completed
- Conditions
- RubellaMeaslesVaricellaMumps
- Registration Number
- NCT00092404
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.
- Detailed Description
The duration of treatment is 6 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1210
Inclusion Criteria
- Healthy children 12 to 18 months of age
Exclusion Criteria
- History or prior exposure to measles, mumps, or rubella
- History of allergic reactions to any component of the vaccines as evaluated by the study doctor
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Antibody response rates to measles, mumps, and rubella at 6 weeks postvaccination 6 weeks postvaccination
- Secondary Outcome Measures
Name Time Method Geometric mean titers to measles, mumps, and rubella by ELISA at 6 weeks postvaccination 6 weeks postvaccination